Stay updated on SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded a footer note 'Revision: v3.3.3'; removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2 (metadata) and no substantive study content changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedThe government funding/operating status banner was removed from the page. The study content and details remain unchanged.SummaryDifference0.4%

- Check58 days agoChange DetectedNo substantial changes detected in the Study Details page content, including the eligibility criteria, interventions, primary/secondary outcomes, or locations; any differences are limited to formatting or rendering. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedMajor update: new operating-status notice and updated version to v3.2.0; removal of the prior v3.1.0 version tag.SummaryDifference3%

- Check88 days agoChange DetectedVersion metadata updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.